BioNTech to wind down cell therapy manufacturing in Maryland, lay off 63 as it ends development of CAR-T drug in testicular cancer
18th June 2025 Uncategorised 0Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant in Gaithersburg, Maryland. In turn, the German company is laying off 63 technical operations staffers at the site.
More: BioNTech to wind down cell therapy manufacturing in Maryland, lay off 63 as it ends development of CAR-T drug in testicular cancer
Source: fierce